Effect of silimarin on non-alcoholic fatty liver disease in childre

Not Applicable

• Conditions: Fatty (change of) liver, not elsewhere classified; onalcoholic fatty liver disease.

• Registration Number: IRCT2015012520781N1
• Lead Sponsor: Qom University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Obese children with non-alcoholic fatty liver manifestations in ultrasonography.
Exclusion criteria : Use of ethanol; use of hepatotoxic drugs; hepatitis B and C; autoimmune hepatitis; Wilson disease; Hemochromatosis; alpha-1 antitrypsin; severe coronary disease; severe lung disease; liver cirrhosis

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
AST. Timepoint: Before and after the treatment. Method of measurement: mg/dL.;ALT. Timepoint: Before and after the treatment. Method of measurement: mg/dL.;Fatty liver disease stage. Timepoint: Before and after the treatment. Method of measurement: Ultrasonography.;TG. Timepoint: Before and after the treatment. Method of measurement: mg/dL.;HDL. Timepoint: Before and after the treatment. Method of measurement: mg/dL.;LDL. Timepoint: Before and after the treatment. Method of measurement: mg/dL.